Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and Metastasis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGA3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGA3 & ITGB1 Heterodimer Protein / ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed to preserve native glycosylation and heterodimeric conformation. |
View ITGA3 Products |
| Gene Delivery | ITGA3 Lentivirus Premade Particles Full-length ORF for stable cell line generation. Ideal for flow cytometry and functional cell adhesion assays. |
View ITGA3 Products |
| Benchmark Ab | Anti-ITGA3 Recombinant Monoclonal Antibody Recombinant positive control derived from benchmark research clones (e.g., ASC-8/332-derived sequences). |
View ITGA3 Products |
| Validator | ITGA3 siRNA Set Target-specific knockdown verification to rule out off-target assay signals. |
View ITGA3 Products |
| Related Target A | ITGB1 (Integrin Beta 1) Essential heterodimerization partner required to form functional VLA-3 (alpha3beta1) integrin receptors. |
View ITGB1 Products |
| Related Target B | LAMA3 (Laminin Subunit Alpha 3) Primary extracellular matrix ligand (component of Laminin-332) mediating ITGA3-driven tumor invasion. |
View LAMA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Heterodimer Integrity | Co-expressed ITGA3/ITGB1 recombinant heterodimer proteins with verified sequence identity and high purity (>95%). |
| Cross-species Cyno/Mouse Evaluation | Human, Cynomolgus, and Mouse ITGA3 ortholog proteins available with strictly controlled endotoxin levels (<1 EU/µg). |
| Lack of Validated Controls | Sequence-verified clinical and research benchmark antibodies included in the catalog. |
| False Positive Knockdown Validation | Highly specific siRNA pools designed for transcript-level target validation. |
Live ITGA3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGA3 therapeutics is intensifying, with major players shifting focus from traditional blocking mAbs to antibody-drug conjugates (ADCs) and radioimmunotherapy. Because ITGA3 is highly overexpressed in metastatic triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC), it serves as an ideal homing receptor for internalization-dependent payloads. As first-generation therapies reach preclinical milestones, the next wave of R&D is targeting tumor-selective epitopes to spare normal epithelial tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Biopharma Consortia / Academic Spin-offs | TNBC, Pancreatic Cancer, Ovarian Cancer | Internalization Assay (Requires high-purity, native-conformation ECD-Fc or stable cell lines) |
| Monoclonal Antibodies (Blocking) | Oncology Research Institutes | Non-Small Cell Lung Cancer (NSCLC) | Ligand Blocking Assay (Requires ITGA3/ITGB1 heterodimer and Laminin-332 recombinant proteins) |
| Radioimmunotherapy (alpha/beta emitters) | Targeted Radiopharmaceutical Developers | Metastatic Solid Tumors | High-affinity Binding & Selectivity Panel (Requires multi-species orthologs to confirm safety margin) |